First Generic Version of Condylox Gel Gets FDA Approval

Padagis has received approval from the Food and Drug Administration (FDA) to market Podofilox Gel, the first generic to Condylox^® Gel, 0.5% in the US.

Podofilox Gel is an antimitotic drug indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). Treatment results in necrosis of visible wart tissue. 

The gel is applied twice daily with the applicator tip or finger for 3 consecutive days, then discontinued for 4 consecutive days. This 1 week cycle may be repeated until there is no visible wart tissue or for a maximum of 4 cycles. 

The generic product from Padagis is expected to be available in December 2023.